Late filing
high
Filing comparison
Karyopharm Therapeutics Inc. filed its quarterly report late and said it expects a significant change in results
expects significant change in results Filed 1 day before the statutory due date.
(the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Quarterly Report”) by the prescribed filing date or the five-day extension permitted by the rules of the Securities and Exchange Commission (the “SEC”). As previously announced, on November 2, 2026, the Company and its subsidiary KPT Texas LLC (together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas, Houston Division (such…
Evidence
- Anticipates significant change
- Yes
- Days past due date
- -1
- Other periodic reports filed
- Yes
- Routine
- No
- Severity
- high
- Source
- Form 12b-25 (notification of late filing)
- Stated reason
- (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Quarterly Report”) by the prescribed filing date or the five-day extension permitted by the rules of the Securities and Exchange Commission (the “SEC”). As previously announced, on November 2, 2026, the Company and its subsidiary KPT Texas LLC (together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas, Houston Division (such…
- Why
- The company told the SEC it could not file a periodic report on time, using Form 12b-25.